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ABSTRACT
Overview. The Centers for Disease Control and Prevention (CDC) health-related
quality of life (HRQoL) indicators are widely used in the general population to de-
termine the burden of disease, identify health needs, and direct public health policy.
These indicators also allow the burden of illness to be compared across different
diseases. Although Lyme disease has recently been acknowledged as a major health
threat in the USA with more than 300,000 new cases per year, no comprehensive
assessment of the health burden of this tickborne disease is available. This study
assesses the HRQoL of patients with chronic Lyme disease (CLD) and compares the
severityofCLDtootherchronicconditions.
Methods. Of 5,357 subjects who responded to an online survey, 3,090 were selected
for the study. Respondents were characterized as having CLD if they were clini-
cally diagnosed with Lyme disease and had persisting symptoms lasting more than
6monthsfollowingantibiotictreatment.HRQoLofCLDpatientswasassessedusing
the CDC 9-item metric. The HRQoL analysis for CLD was compared to published
analysesforthegeneralpopulationandotherchronicillnessesusingstandardstatisti-
calmethods.
Results. Compared to the general population and patients with other chronic dis-
eases reviewed here, patients with CLD reported significantly lower health quality
status, more bad mental and physical health days, a significant symptom disease
burden, and greater activity limitations. They also reported impairment in their
ability to work, increased utilization of healthcare services, and greater out of pocket
medicalcosts.
Conclusions. CLD patients have significantly impaired HRQoL and greater health-
care utilization compared to the general population and patients with other chronic
diseases. The heavy burden of illness associated with CLD highlights the need for
earlierdiagnosisandinnovativetreatmentapproachesthatmayreducetheburdenof
illnessandconcomitantcostsposedbythisillness.
Subjects Epidemiology, Infectious Diseases, Statistics
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Lyme disease is the most common vector-borne disease in the United States. It is caused
by the spirochete Borrelia burgdorferi and transmitted via tick bite. In its early, or acute,
form, the disease may cause a hallmark erythema migrans (EM) rash and/or flu-like
symptoms such as fever, malaise, fatigue, and generalized achiness (Aucott et al., 2009).
Unfortunately, many patients are not diagnosed early because the carrier tick may be as
small as a poppy seed, its bite is painless, and the hallmark EM rash does not occur in a
significantpercentageofpatients(Aucottetal.,2009).
The CDC estimates that roughly 300,000 people (approximately 1% of the U.S.
population) are diagnosed with Lyme disease each year (Centers for Disease Control and
Prevention, 2013b). This figure is 11/2 times higher than the number of women diagnosed
with breast cancer each year in the USA (approximately 200,000), (Centers for Disease
Control and Prevention, 2013a) and 6 times higher than the number diagnosed with
HIV/AIDS each year in the USA (50,000) (Centers for Disease Control and Prevention,
2013c). A proportion of patients with Lyme disease develop debilitating symptoms that
persistintheabsenceofinitialtreatmentorfollowingshort-courseantibiotictherapy.This
condition is commonly referred to as post-treatment Lyme disease (PTLD) or chronic
Lyme disease (CLD). It is estimated that as many as 36% of those diagnosed and treated
earlyforLymediseaseremainillaftertreatment(Aucottetal.,2013).
Although the CDC is tracking the spread of Lyme disease, very little data is available
aboutitsimpact onpatientqualityoflife,healthcareserviceneedsandworkcapability.The
CDC has developed a broad health-related quality of life (HRQoL) metric that is included
in numerous government population surveys and sets goals for Healthy People 2020
(US Department of Health and Human Services, 2011). The HRQoL metric is a 9-item
survey (4-item Healthy Days Core Module and 5-item Healthy Days Symptoms Module)
that is used to assess health in the general population, determine the symptom burden
of chronic diseases, identify health disparities and unmet health needs, evaluate progress
on achieving goals, and inform public health policy (Moriarty, Zack & Kobau, 2003). In
addition, it permits the burdens of different diseases to be compared despite the widely
varying time course, symptom patterns, functional impairment, and clinical severity
associated with these diseases (Cook & Harman, 2008; Institute of Medicine, 2012). The
patient-centered HRQoL indicators are considered to be robust predictors of subsequent
healthoutcomesandhealthsystemutilization(DeSalvoetal.,2005).
ThepurposeofthisstudyistodocumenttheseverityofCLDcomparedtootherchronic
conditionsusingtheCDCHRQoLmetric.Inaddition,wediscussHRQoLindicatorsinthe
contextofphysicalandmentalhealth,healthcareserviceutilizationandworkproductivity.
To our knowledge, this is the first study that examines these HRQoL indicators in persons
withCLD.
PATIENT SELECTION AND CHARACTERISTICS
The sample for this analysis was gathered in early 2013 from individuals who participated
in or visited Lyme disease patient-centered online forums in which the survey was posted
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Descriptionofsample Count(%oftotalsample)
Total sample 5,357 (100%)
Satisfy IRB requirements, not duplicates 5,057 (94.4%)
Clinical diagnosis confirmed by EM rash or positive serology
(excluding ELISA or IFA alone)
3,246 (60.6%)
Symptoms persist at least six months after receiving at least 21 days
of antibiotic treatment for Lyme disease.
3,090 (57.7%)
Working sample 3,090 (57.7%)
Notes.
EM,erythemamigrans;IRB,institutionalreviewboard;ELISA,enzyme-linkedimmunosorbentassay;IFA,immunoflu-
orescence assay.
or publicized. The survey was conducted by LymeDisease.org, a grassroots organization
that promotes Lyme disease education and research, and written informed consent was
obtained from each subject. Analysis of the survey data was exempted from review by the
Carnegie Mellon University Institutional Review Board (IRB) because none of the data
contained identifiable personal information. A total of 5,357 subjects responded to the
survey,ofwhichafinalsampleof3,090wasexamined.
Table 1 shows the original sample of 5,357 respondents and the exclusion criteria that
ledtoafinalsampleof3,090subjects.Tobeincludedinthesample,respondentsmusthave
been clinically diagnosed with Lyme disease, have the EM rash and/or have supporting
laboratorytestsconfirmingthediagnosis,andhavepersistingsymptomsformorethansix
monthsfollowingatleast21daysofantibiotictreatment.Anadditionalcohortofclinically
diagnosed Lyme disease patients who had symptoms for less than six months was also
identifiedandincludedonlyintheanalysisofdiseaseprogressionovertime(seeFig.1A).
Respondents whose diagnosis was made clinically without supporting laboratory tests
or an EM rash were excluded, and those with only a positive Lyme disease enzyme-linked
immunosorbent assay (ELISA) or immunofluorescence assay (IFA) to support their
diagnosis were also excluded from the study (a total of 23.8%). A majority of the working
sample (a total of 59.5%) was diagnosed by EM rash (6.3%), CDC-positive two-tier test
result (ELISA and Western blot, 29.7%), or based on a CDC-positive Western blot alone
(23.5%). The rest of the cohort (40.5%) was clinically diagnosed with a positive Western
blot using non-CDC interpretive criteria, a positive polymerase chain reaction or culture
test, or a positive cerebrospinal fluid test for B. burgdorferi. While only 6.3% reported
EM rash as the basis of their clinical diagnosis, 39.3% reported having a rash when they
contractedthedisease.
Table 2 shows the demographic characteristics of the resulting sample. In terms of
diagnosis, 7.9% of respondents were not diagnosed until at least 3 months after the
onset of symptoms, 16.6% were not diagnosed for at least 6 months, and 61.7% were not
diagnosed for at least 2 years. Approximately half (50.5%) of the sample reported having
Lyme disease for more than 10 years. Tickborne coinfections confirmed by serological
testing were reported by 53.3% of respondents: 23.5% reported at least one co-infection
Johnson et al. (2014), PeerJ, DOI 10.7717/peerj.322 3/21Figure 1 (A) Percentage of survey respondents reporting fair or poor health as a function of length of
illness. CLD, chronic Lyme disease. The non-CLD population (0–6 months) is included here to illustrate
theprogressionofdiseaseovertime.Thispopulationwasotherwiseexcludedfromthestudy(seeTable1).
(B) Percentage of survey respondents reporting fair or poor health compared to the general population
andpatientswithotherchronicdiseases.References:1.CentersforDiseaseControlandPrevention(2010d);
2. Burns et al. (1997); 3. Wolfe et al. (1997); 4. Hoge et al. (2007); 5. Centers for Disease Control and
Prevention (2009); 6. Yazdany et al. (2011); 7. Becker & Stuifbergen (2009); 8. Lackner et al. (2006);
9. Rangnekar et al. (2013); 10. Fiorillo, Lansky & Bethell (2001).
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Variable Count(%ofworkingsample)
Female 2,364 (82.6%)
Mean age 48.2 years (±12.8)
Education
High school or less 256 (9%)
Some college 751 (26%)
College graduate 1134 (40%)
Graduate school degree 723 (25%)
Familyincome
Less than $20k 383 (14%)
$20–40k 393 (14%)
$40–60k 440 (16%)
$60–80k 396 (14%)
$80–100k 383 (14%)
$100k + 785 (28%)
Geography
Northeast 984 (35%)
Midwest 371 (13%)
South 673 (24%)
West 813 (29%)
and 29.8% reported two or more co-infections. More specifically, 32.3% of respondents
reportedlaboratoryconfirmeddiagnosiswithBabesia,28.3%withBartonella,14.5%with
Ehrlichia, 4.8% with Anaplasma, 15.1% with Mycoplasma, 5.6% with Rocky Mountain
Spotted Fever, and 0.8% with Tularemia. Recollection of a tick bite was reported by 39.6%
ofrespondentsand39.4%reporteda“bulls-eye”orirregularrash.
Among respondents, 51.8% were not taking antibiotics. Of those on antibiotics, 92.3%
reported taking oral antibiotics, with the remainder taking parenteral antibiotics. Many
reasons were given for not being on antibiotics, including using other treatment methods
(18.4%), currently well or in remission (10.6%), financial constraints (8.1%), no access to
treatingphysicians(8.0%),treatmentnolongerhelping(7.7%),andtreatmentsideeffects
(7.4%).
STUDY METHODS
HRQoL was measured using the CDC 9-item metric (4-item Healthy Days Core Module
and 5-item Healthy Days Symptoms Module). Respondents rated their overall health
quality as excellent, very good, good, fair or poor. Respondents also answered questions
regarding how often during the previous 30 days they experienced vitality, poor physical
health, poor mental health, depression, anxiety, and sleep difficulties. In addition,
respondents were asked the number of days that their activity was limited due to pain as
well as poor physical or mental health. The list of symptoms used in the symptom severity
questions were drawn from a review of Lyme research as well as a small online survey that
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Variable Mean(S.D.)
4-itemHealthyDaysCoreModule
General health rating (Excellent = 1, Poor = 5) 4.0 (1.0)
Physical health not good (# days out of 30) 20.1 (10.5)
Mental health not good (# days out of 30) 15.5 (10.8)
Physical or Mental health limited usual activities (# days out of 30) 16.8 (11.2)
5-itemHealthyDaysSymptomsModule
Pain limited activities (# days out of 30) 16.5 (11.7)
Sad, blue or depressed (# days out of 30) 12.4 (10.5)
Worried, tense or anxious (# days out of 30) 15.8 (11.1)
Not enough rest (# days out of 30) 20.3 (10.1)
Very healthy/full of energy (# days out of 30) 3.5 (6.2)
pilot-testedsurveyquestionsforapreviousstudyof2,424patientsregardingaccesstocare
(Cairns & Godwin, 2005; Johnson, Aylward & Stricker, 2011; Logigian, Kaplan & Steere,
1990;Shadicketal.,1994;Steere,1989).
Healthcare utilization was measured using the criteria employed by the Medical
Expenditure Panel Survey (Agency for Healthcare Research and Quality, 2014). Visits to
doctorsorotherhealthcareprofessionals,visitstoemergencydepartments,inpatientstays,
andhomecarevisitswerereported.Additionalsurveyquestionsweredevelopedregarding
severityofsymptoms,employmentstatusandclinicalpresentationofLymedisease.
STATISTICAL ANALYSIS
IBM’sSPSSversion21wasusedtoconductthisanalysis.WherescalarvariablesforHRQoL
or healthcare utilization were compared with those of other chronic conditions or the
generalpopulation,two-tailedt testswereperformed.Wherevariableswerenon-normally
distributed, nonparametric Mann–Whitney U tests or one-sample Wilcoxon signed rank
tests were used. Where subgroups with multiple variables were compared, familywise
error rate was addressed by applying Bonferroni or Dunnet T3 corrections, depending
on the distribution normality of the variables. Where binary variables were compared,
oddsratioswithconfidenceintervalsandpvaluesweredetermined.Reportedsamplesizes
and means were used to compute confidence intervals of comparison variables. P values
<0.05 were considered significant. Correlations between symptoms, time to diagnosis,
time since infection, and self-reported health status, all ordinal variables, were analyzed
using Spearman coefficients. Ordinal regression analysis was performed to determine the
impactofthesefactorsonself-reportedhealthstatus.
RESULTS
CDC HRQoL health module
Table 3 shows the scoring of CLD patients on the HRQoL metric. Respondents reported
very poor HRQoL, with a high prevalence of fair or poor self-reported health status.
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ClinicaldiagnosisbasedonEM
rashand/ortwo-tieredserology
Clinicaldiagnosisbasedonother
laboratorydataa
Fullworking
sample
Count 1087 2003 3090
% of Total 35.2% 64.8% 100.0%
% not diagnosed within 6 months of symptom onset 67.8%** 84.1%** 78.4%
Fair or Poor General Health 71.6% 72.6% 72.3%
Number of severe or very severe symptoms 3.3 3.2 3.2
At least one severe or very severe symptom 74.3% 71.5% 72.5%
Number of poor physical health days 19.6 20.4 20.1
Number of poor mental health days 15.5 15.5 15.5
Number of visits to a health care professional 19.4 19.4 19.4
Number of visits to the emergency room 1.2 1.0 1.1
% with inpatient stays 18.1%* 13.6%* 15.2%
% with homecare visits 13.3% 12.5% 12.8%
% with at least $5,000 in out-of-pocket Lyme-related
expenses
37.3%** 46.4%** 43.2%
% who have stopped working 39.4% 42.4% 41.3%
% who have changed work hours or role 28.3% 29.7% 29.2%
Notes.
* P < 0.01.
** P < 0.001.
All other categories had non-significant differences.
a Includes patients diagnosed by CDC positive Western blot, non-CDC positive Western blot, positive PCR, positive culture or positive lumbar puncture.
In addition, respondents reported many physically and mentally unhealthy days, many
dayswithactivitylimitationsduetounhealthydaysorduetopain,andmanydaysmarked
bydepression,anxietyandlackofrest.
Table 4 compares the HRQoL, health care utilization, and employment impact of
those whose diagnosis was based on EM rash or CDC-positive two-tiered serology (EM
rash/CDC serology) vs. those whose diagnosis was based on positive CDC Western blot,
non-CDCWesternblot,PCR,cultureand/orspinaltap(otherlaboratorydata).Therewere
no significant differences between the two groups with the exception that patients who
reported EM rash/CDC serology were diagnosed more quickly, had a greater number of
inpatient stays in the last year, and incurred less out-of-pocket medical expenses. Because
there are no significant differences in the majority of metrics and the few differences are
slight,thetwogroupsaretreatedasoneforthepurposeofthisanalysis.
Overall health status
Figure 1 shows the comparative health status of patients with CLD. Figure 1A shows that
greatertimetodiagnosisandgreatertimesinceinfectionweresignificantlycorrelatedwith
poorer self-reported health status (ρ = 0.174 and 0.155, p < 0.01 and 0.01, respectively).
Only 23% of those with Lyme disease for less than six months reported their healthcare
statusaspoor,comparedwith56%atoneyearand72%at5–10years.Figure1Bcompares
the health status of survey respondents with other populations. Among CLD patients,
Johnson et al. (2014), PeerJ, DOI 10.7717/peerj.322 7/21Figure 2 (A) Severity of common respondent symptoms. (B) Frequency of good or bad CDC symptom
days per month reported by respondents.
72.3% reported fair or poor health status, significantly exceeding the 16.3% of the general
populationreportingfairorpoorhealth(OR = 13.38,CI = 12.35–14.49,p < 0.0001).This
frequency also significantly exceeds that of other chronic diseases, with congestive heart
failure (62%) (Burns et al., 1997) and fibromyalgia (59%) (Wolfe et al., 1997) being the
closestintermsoffairorpoorhealth(OR = 1.59,CI = 1.31–1.94,p < 0.0001).
Symptom severity
Figure2showstheseverityofsymptomsandnumberofbadsymptomdaysinpatientswith
CLD. Respondents, on average, reported 3.2 symptoms described as severe or very severe,
with 12.7% reporting at least one symptom and 63.3% reporting two or more symptoms
assevereorverysevere.The72%ofrespondentswhoreportedfairorpoorhealthaveraged
4.04severeorveryseveresymptomscomparedwith1.07amongthosereportinggood,very
good,orexcellenthealth.
Johnson et al. (2014), PeerJ, DOI 10.7717/peerj.322 8/21Figure 2A shows that CLD patients reported the following ten symptoms as severe
or very severe: fatigue (48.3%), sleep impairment (40.8%), joint pain (39.1%), muscle
aches (36.1%), other pain (34.4%), depression (33.8%), cognitive impairment (32.3%),
neuropathy(31.6%),headaches(22.7%)andheart-relatedissues(9.6%).Thesesymptoms
were all significantly correlated with each other, tending to present simultaneously with
similar levels of severity (Spearman correlation coefficient range from ρ = 0.762 to
ρ = 0.300, p < 0.01). All ten symptoms were significantly correlated with self-reported
status(Spearmancorrelationcoefficientsfromρ = 0.622toρ = 0.307,p < 0.01).Ordinal
regressionanalysisconfirmedtherankingofthesymptomcorrelations,identifyingfatigue
(ρ = 0.622,p < 0.01), other pain (ρ = 0.524,p < 0.01), and cognitive impairment
(ρ = 0.506,p < 0.01)asthemostimpactfulvisavisself-reportedhealthstatus.
Figure 2B shows that CLD patients also reported a high number of bad symptom days
on the CDC symptom module. The number of days with activity limitation due to pain
(16.5)reportedbyCLDpatientssignificantlyexceededdayswithactivitylimitationdueto
pain caused by cancer (13.1), cardiovascular disease (9.2) and emotional problems (8.8)
(t = 15.73,p < 0.001) (Richardson et al., 2008). Bad mental days (15.5) reported by CLD
patients were strongly correlated with anxious (15.8) or depressed days (12.4) (ρ = 0.737
and 0.791, p < 0.01 and 0.01, respectively). The number of unrested days (20.3) reported
by CLD patients was associated with the high severity of fatigue reported by these patients
(ρ = 0.469,p < 0.01). The CLD figure significantly exceeded the number of unrested
days reported by people with cancer (14.5), cardiovascular disease (11.2) and emotional
problems(15)(t = 28.87,p < 0.001)(Richardsonetal.,2008).
Healthy days and activity limitations
Figure 3 shows the impact of CLD on physical and mental health. Physical and mental
unhealthy days measure how often individuals rated their physical or mental days as not
good in the past 30 days. Respondents with chronic Lyme disease were compared to the
general population and to patients with other chronic diseases, including patients with
chronic conditions severe enough to also have an activity limitation (right side of the
chart).Comparedtothegeneralpopulation,CLDpatientsreportedsignificantlymorebad
physical health days (20.1 vs. 3.7, t = 84.6,p < 0.001) and significantly more bad mental
health days (15.5 vs. 3.5, t = 60.3,p < 0.001). They also reported more days that poor
physical or mental health limited usual self care, recreation or work activities compared to
thegeneralpopulation(16.8vs.2.3,t = 70.2,p < 0.001)(graphnotshown).
As seen in Fig. 3, the closest chronic disease in terms of both bad physical and mental
days was chronic lower back pain (18.7 and 13.8). Cancer patients with an activity
limitation had similar bad physical days (18.8), while patients with depression and an
activity limitation had similar bad mental days (17.9) (Aslan et al., 2010; Richardson et al.,
2008).
Increased utilization of services
Figure 4 shows that respondents with CLD reported significantly greater healthcare
utilization than people in the general population. Compared with the general population,
Johnson et al. (2014), PeerJ, DOI 10.7717/peerj.322 9/21Figure 3 Number of poor physical and mental days per month of patients with CLD compared to the
generalpopulationandotherchronicdiseases. References: 1. Centers for Disease Control and Prevention
(2010d); 2. Aslan et al. (2010); 3. Richardson et al. (2008).
Figure 4 Healthcare services utilization of patients with CLD compared to the general popula-
tion. References: 1. Centers for Disease Control and Prevention (2010a); 2. Centers for Disease Control and
Prevention (2010b); 3. Centers for Disease Control and Prevention (2010c); 4. National Center for Health
Statistics (2012b); 5. Agency for Healthcare Research and Quality (2010).
Johnson et al. (2014), PeerJ, DOI 10.7717/peerj.322 10/21Figure5 CurrentemploymentstatusofrespondentswithCLDcomparedtothegeneralpopulation.
CLD patients visited doctors and healthcare professionals 5 times more often (19.4 vs.
3.7) (Centers for Disease Control and Prevention, 2010a; Centers for Disease Control and
Prevention, 2010b) and emergency departments more than twice as often (1.09 vs. .43)
(t = 32.4 and 10.825, p < 0.001 and 0.001, respectively) (Centers for Disease Control and
Prevention, 2010c). Furthermore they were almost twice as likely to stay overnight in a
hospital (15.2% vs. 7.9%) (National Center for Health Statistics, 2012b) and were roughly
six timesmore likely toreceive or payfor homecare visits(12.8% vs. 2.0%)(OR = 2.1 and
7.2,CI = 1.9–2.3and6.4–8.0,p < 0.0001and0.0001,respectively)(AgencyforHealthcare
ResearchandQuality,2010).
Respondents also reported greater out-of-pocket healthcare-related expenses during
the past year compared to the general population. Out-of-pocket expenses included
deductibles, copayments, and payments for services not covered by health insurance that
werepaidbyrespondentsortheirfamiliesinthepastyearforcostsrelatedtoLymedisease.
Theydidnotincludeover-the-counterremedies.AmongCLDrespondents,69%reported
spending more than $2,000 and 43% more than $5,000 on out-of-pocket expenses in
the preceding year. In comparison, only 20% of the general population exceeded $2,000
annually (including dental costs) and approximately 6% exceeded $5,000 (OR = 9.4 and
13.4, CI = 8.6–10.2 and 12.3–14.6, P < 0.0001 and 0.0001, respectively) (National Center
forHealthStatistics,2012a).
Productivity losses
Figure 5 shows the employment status of CLD patients. Respondents suffered greater
impairment of their ability to work compared to the general population. In March 2013,
81.0% of the general population ages 25–54 were employed, compared with 45.9% of
CLD respondents in that age range (42.1% of the entire adult CLD sample) (OR = 0.199,
Johnson et al. (2014), PeerJ, DOI 10.7717/peerj.322 11/21CI =0.181–0.219,P <0.0001)(Toossi,2012).Approximately42%ofrespondentsreported
that they stopped working as a result of Lyme disease (with 24% reporting that they
received disability as a result of CLD), while 25% reported having to reduce their work
hours or change the nature of their work due to Lyme disease. These figures compare
with 6.3% of the USA population that is unable to work due to health problems and 3.1%
that are limited in work due to health problems (OR = 10.6 and 10.4, CI = 9.8–11.5 and
9.6–11.4,P < 0.0001and0.0001,respectively)(CentersforDiseaseControlandPrevention,
2010d). Those respondents who were able to continue working reported missing 15
days of work during the preceding 240-day work year, and they reported an inability to
concentratewhileatwork(so-calledpresenteeism)during42daysofworkinthepreceding
yearduetoillness.
DISCUSSION
Chronic medical conditions may be characterized by time course, pathogenesis, symptom
patterns, late stage manifestations, functional impairment or activity limitation, clinical
severity, and management burden on caregivers and society (Institute of Medicine, 2012)
These conditions come with varying levels of severity. While some diseases are highly
disabling, others are not (Anderson, 2010). This variability makes comparison between
diseasesproblematic.UseoftheCDCHRQoLmetricprovidestheopportunitytocompare
the health status of CLD patients to that of the general population and patients with other
chronicdiseasesdespitethevariabilityoftheseconditions.
Self-rated health is considered to be a more powerful predictor of mortality and
morbidity than many objective health measures (New York State Department of Health
Disability and Health Program, 2007). How people view their health is strongly correlated
with healthcare burden and outcomes. More specifically, people in the general population
who regard their health status as fair or poor report more bad physical and mental
days, more days with an activity limitation, more bad days due to pain, depression, or
anxiety, more sleepless days, higher healthcare utilization and increased medical expenses
(Moriarty, Zack & Kobau, 2003). They also experience fewer days when they are full of
energy/vitality(Moriarty,Zack&Kobau,2003).
As noted in Fig. 1, patients with CLD reported fair or poor health status significantly
more frequently (72%) compared to people in the general population (16%) and patients
with other chronic conditions. Consistent with this compromised health status, CLD
patients reported a significant symptom disease burden (Fig. 2), more bad physical and
mental health days compared to the general population and most other chronic diseases
reviewed here (Fig. 3), and increased utilization of healthcare services resulting in more
medical costs compared to the general population (Fig. 4). CLD patients also reported
greater activity limitations and impairment in their ability to work (Fig. 5). The degree
of compromised health reported by respondents is also reflected by the need for special
medical aids. Approximately 22.8% of respondents reported requiring special medical
equipment as a result of Lyme disease, with 17.2% requiring the use of either a cane
(13.7%)and/orawheelchair(6.8%).
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related to fatigue, joint pain, headaches, other pain, muscle aches, neuropathy, cognitive
impairment, sleep impairment or mood impairment, and 63% reported more than one
symptom as severe or very severe (Fig. 2). The strongest driver of health status in our
samplewas fatigue.Chandraand colleagues notedmoderateto severelevelsof fatigueand
painintheirsampleofpatientswithCLD,andtheyalsofoundthatfatiguewastheprimary
driver of poor physical component scores in their patients (Chandra, Keilp & Fallon,
2013). In a recent study by Aucott et al. (2013), 20–45% of Lyme disease patients who
were diagnosed and treated early reported fatigue, widespread pain or sleep disturbance
six months later. Moreover, in accordance with the Aucott study, the frequency of fatigue
and sleep impairment reported here exceeded that found in the general population, while
the frequency of pain exceeded the level reported in fibromyalgia (Aucott et al., 2013). The
severity of symptoms reported here also mirrors the findings of Klempner et al. (2001)
that patients with CLD may suffer a degree of disability equivalent to that of patients with
congestiveheartfailure.
Compared to the general population and patients with other chronic diseases, CLD
respondents reported significantly more bad physical and mental health days (Fig. 3).
They also reported more days in which poor physical or mental health limited usual self
care, recreation or work activities compared to the general population. CLD respondents
reported more bad physical days than patients with chronic low back pain, asthma,
diabetes, cancer, depression and cardiovascular disease, and more bad mental days than
patients with each of these diseases with the exception of depression. In a study using a
different quality of life scale, the mental and physical component scores of patients with
CLD were found to be worse than the scores of patients with heart disease, diabetes,
depression, cancer and osteoarthritis (Cameron, 2008). Moreover, like other chronic
physical diseases, the number of bad physical days was significantly higher than the
numberofbadmentaldays(Cameron,2008;Fiorillo,Lansky&Bethell,2001).
Chronic illnesses account for 84% of healthcare costs, and those with chronic illnesses
arethegreatestusersofhealthcareservices(Anderson,2010).Onestudyfoundthatpeople
in the highest 5 percent of the medical expense category were 11 times more likely to be
in fair or poor physical health (Stanton, 2006). Furthermore, the costs for patients with
an activity limitation are roughly double those of patients without an activity limitation
(Anderson, 2010). Compared with the general population, CLD patients were five times
more likely to visit doctors and healthcare professionals and more than twice as likely to
be seen in an emergency department. In addition, they were almost twice as likely to stay
overnight in a hospital and roughly six times more likely to receive or pay for home care
visits (Fig. 4). This markedly increased healthcare utilization is undoubtedly associated
with increased healthcare costs, although this study was not designed to measure total
medicalexpenditures.
We also found that patients with CLD incurred high out-of-pocket expenses compared
with other diseases. The percentage of CLD patients spending in excess of $5,000 in
out-of-pocket costs was 46% compared to 5% in the general population. This may
Johnson et al. (2014), PeerJ, DOI 10.7717/peerj.322 13/21reflect the fact that CLD patients had greater co-payments as a result of more frequent
physician visits. In addition, it is likely that these physician visits would be out of network
becausemanyinsurershaveadoptedrestrictiveLymediseaseguidelinesandmaynotcover
extendedtherapywithantibioticsorothermedicationsoftenusedforCLDtreatment.
As noted in Table 4, respondents who reported that their diagnosis was based on EM
rash/CDC serology were diagnosed more often within six months (84.1% vs. 67.8%)
but incurred more inpatient stays (18.1% vs. 13.6%) than patients diagnosed by other
laboratory data. In addition, respondents who were diagnosed by other laboratory data
had a higher rate of annual out-of-pocket costs exceeding $5,000 (46.4% vs. 37.3%). The
reason for this difference is unclear and requires further study. A possible explanation for
the fact that those diagnosed by other laboratory data had fewer inpatient stays may be
that they avoided such stays because they were bearing a greater portion of costs due to
insurancedenials.
Whilegoodhealthaffectsindividualwell-beingandhealthcareutilization,italsoaffects
employee productivity. Approximately 80% of the cost of chronic illness is productivity
losses (Devol & Bedroussian, 2007). As might be expected, the ability of CLD patients
to retain full time work was adversely affected as a result of their large number of days
with activity limitations due to poor health (Fig. 5). A substantial percentage of CLD
patients reported that their Lyme disease impaired their ability to work, resulting in either
a reduction in work hours, a modification of the type of work performed or quitting work
altogether. Other studies have found that a quarter of CLD patients were on disability
due to their disease at some point in their illness, with most disability lasting more than
two years (Johnson, Aylward & Stricker, 2011). Respondents reported an average of two
healthcare-relatedvisitspermonth,whichalsoadverselyimpactedtheirabilitytowork.
While it is beyond the scope of this study to calculate the economic cost of this loss
of productivity, it would appear to be substantial. Loss of productivity results when
chronically ill workers are unable to work, reduce their work hours, take excessive sick
days or perform below par while at work. Diminished work performance exacts a toll
on the worker, the worker’s family and the employer. Ultimately, the government and
society also suffer because of the reduction in productivity of these compromised workers
(Devol&Bedroussian,2007).
Internet surveys can be effectively delivered to the general population on a large scale.
An increasing number of survey studies have turned to the internet because of the high
costs and decreased response rates for telephone surveys, mail surveys, and face-to-face
interviews, and online methods of data collection have been found to be comparable to
traditional methods (Liu et al., 2010; van Gelder, Bretveld & Roeleveld, 2010). Moreover,
unlike more objective medical outcomes, HRQoL survey data must be collected directly
fromthepatient,whichmakesinternetdatacollectionideal(Bhinderetal.,2010).
Animportantconsiderationininternetsurveysisselectionbias,whichmayimpactgen-
eralizability (Liu et al., 2010). Researchers control for this bias by using demographically
balancedpanelsandbyusingweightingadjustmentstocompensateforresponsevariation
from known populationvalues (Liu etal., 2010). InLyme disease,however, thesemethods
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characteristicsofpatientsandCLDarenotwelldefined,andthegeneralizabilityofresearch
findings to the clinical population has been problematic. Second, the relatively low rate of
Lyme disease reporting under the CDC surveillance system would require extraordinarily
largedemographicallybalancedpanelstoachieveameaningfulsamplesize.
As the CDC’s recent revision of the annual incidence of Lyme disease from 30,000
to more than 300,000 cases suggests, the true incidence and spectrum of disease is still
in an emerging state. The CDC’s revision of the surveillance case numbers arose from
their preliminary review of three CDC funded studies that did not utilize the restrictive
CDC surveillance criteria, but rather relied on self-reported diagnosis, insurance coding
by healthcare providers, and positive serology. Hence, the increased incidence numbers
suggest that the surveillance system does not reflect the full spectrum of the disease seen
clinically.
The 30,000 patients captured annually in the surveillance system are outnumbered
ten-to-one by those who are not, and the difference between those counted as cases and
the270,000+whoarenotisunknown.Whetherthepopulationdemographicsthatemerge
uponfurtherstudyconformtothosecurrentlyrepresentedintheCDCsurveillancesystem
remains to be seen. Points of variation may include clinical characteristics (e.g., presence
of EM rash or symptom profiles) or demographic characteristics (e.g., age, gender, or
geographic distribution of reported cases). These issues negatively impact the ability
and desirability of weighting the sample to reflect a normal distribution of the patient
population.
In this study 39.3% of patients reported the presence of an EM rash compared to
69% of cases included in the CDC surveillance numbers (Centers for Disease Control and
Prevention, 2008). Possible reasons for this discrepancy include (a) patients may not recall
an EM rash that was present, (b) the CDC surveillance reporting system may have an
implicit selection bias toward those with an EM rash, or (c) patients without an EM rash
may be less likely to receive treatment that would prevent progression of the disease. For
example, Aucott reports that 54% of Lyme disease patients who present without a rash are
misdiagnosed (Aucott et al., 2009). Physicians may fail to diagnose Lyme disease when the
EMrashisirregularorhomogeneousratherthanthetextbook“bulls-eye”shape(Schutzer
et al., 2013; Smith et al., 2002). It is also important to recognize that even among the CDC
surveillance cases there is considerable variation in the reported incidence of EM rash in
different parts of the USA, ranging from 51% to 87% depending on the state (Centers for
DiseaseControlandPrevention,2008).Inaddition,incidencebyageandsexdistributionof
CDCsurveillancecasesvarybystate(CentersforDiseaseControlandPrevention,2008).Itis
not known whether these clinical and demographic variations reflect reporting anomalies
orgeographicalstraindiversityofB. burgdorferi.
Generalizability issues have complicated the four National Institutes of Health
(NIH)-funded randomized controlled trials on CLD, where researchers screened large
numbers of patients to yield small sample sizes (Bhinder et al., 2010). Indeed, one study
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al., 2008). The trade-off between internal validity and external generalizability in clinical
trialsiswidelyrecognized(Bhinderetal.,2010;Donkinetal.,2012).Howeverwhile25%of
those with other diseases may meet the entry criteria for a clinical trial, only 10% of those
withCLDmeettheserestrictiveentrycriteria(Donkinetal.,2012).
Our findings suggest that the CDC and NIH should include questions regarding
Lyme disease in national population surveys that would permit researchers to accurately
characterize the annual incidence, prevalence, and demographic distribution of Lyme
disease in the United States. However, in the meantime, it is important to recognize that
generalizability problems are common given the current state of the science in Lyme
disease. While our study does not seek to characterize a well-defined population of
patients, it provides important insight into the clinical characteristics of the emerging
CLDpopulation.
STRENGTHS AND LIMITATIONS
This study has several strengths. First, to our knowledge it is the first study to evaluate
CDC HRQoL of patients with CLD. Second, the sample size of the study was robust
and permitted analysis of multiple patient variables. Third, the use of a standardized
questionnaireallowedin-depthanalysisofCLDpatientsaswellasmeasurablecomparison
between these patients, the general population and other chronic diseases. Finally, despite
the exclusion criteria utilized in the study, the sample population was much more diverse
than the populations examined in published randomized controlled trials of CLD. For
example, our sample included patients with tickborne coinfections who were generally
not evaluated in other Lyme disease studies. Thus the study results should be more
generalizabletothebroadspectrumofCLDpatientscomparedtotheresultsofthelimited
randomizedcontrolledtrialsperformedtodate(Bhinderetal.,2010;Liuetal.,2010).
There are limitations to our study. First, our sample is self-selected from participants
who are sick enough (and Internet-savvy enough) to seek online support for their
illness. Because respondents were not a randomly drawn sample, the results may not
be fully representative of persons living with Lyme disease in the United States. Second,
respondents reported a large number of activity limitation days. It has been noted that
patients limited by a condition may represent the most severely ill individuals with
that condition (Richardson et al., 2008). This matches our expectation that our sample
represents people who are more sick rather than less sick. Along these lines, survey results
were limited to patients with CLD who reported persistent symptoms for six months or
more. Patients with acute Lyme disease who are diagnosed and treated early would be
expectedtohavelessqualityoflifeimpairment,asnotedinFig.1A.
A third limitation is that the results are based on self-reported information without
diagnostic confirmation. However, self-reported information has been found to have
acceptable levels of reliability when compared to medical chart information (Bayliss et
al., 2012). Moreover, self-rated health is considered to be a reliable indicator of perceived
health and personal well-being and may be a more powerful predictor of mortality and
Johnson et al. (2014), PeerJ, DOI 10.7717/peerj.322 16/21morbidity than many objective measures of health (New York State Department of Health
DisabilityandHealthProgram,2007).
A fourth limitation is that the sample population is slightly older (about 1.5 years)
than the general population, and this difference may impact both health status and
utilization of health services. In addition, the existence of comorbidities, which may
increase reported health status and healthcare utilization was not addressed in the survey.
The high percentage of women in this sample may reflect the higher percentage of females
seeninsomeCLDstudiesaswellasthefemale-skeweddemographicsoftenseeninpatient
surveyresponses(Boscardin&Gonzales,2013;Stricker&Johnson,2009).
CONCLUSIONS
Based on our survey results, CLD patients suffer from significantly impaired HRQoL,
utilize healthcare services more frequently and have greater limitations on their ability to
work compared to the general population and patients with other chronic diseases. The
heavy burden of illness associated with CLD highlights the need for earlier diagnosis of
Lyme disease to avoid progression to CLD, as well as the need for innovative treatment
approachestoreducetheburdenofillnessandconcomitantcostsposedbythisillness.
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